Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

French To Launch Two-Year Medicinal Cannabis Pilot Project

Executive Summary

A two-year pilot program in France will look at the practicalities of prescribing medicinal cannabis for patients with one of five specific conditions.

You may also be interested in...



UK’s NICE Not Convinced By Cannabis-Based Medicines

New draft guidance from the health technology assessment body NICE says that more evidence is needed on cannabis-based medicines before they can be more widely used. In the meantime, it says they should not be used in chronic pain, epilepsy or spasticity in multiple sclerosis, while nabilone may be used for chemotherapy-related sickness.

NZ Plans New Medicinal Cannabis Regulatory Scheme & Agency

A new regulatory scheme for medicinal cannabis products, complete with a brand new agency, is on the cards in New Zealand, based on a strict licensing and quality control system that is intended to increase the supply of, and patient access to, such products.

UK Committee Attacks Pharma Over Lack Of Medicinal Cannabis Research

The pharmaceutical industry has come under attack by a UK parliament committee for failing to make medicinal cannabis products available for clinical trials, saying that a "robust research base" is needed on which to base future treatment decisions.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS125588

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel